Qingyuan Kaiwu Secures Tens of Millions in Pre-A+ Funding to Accelerate Expansion in Laboratory Automation Market

VCBeat has learned that an innovative life science tools supplierBeijing Qingyuan Kaiwu Technology Co., Ltd. (hereinafter referred to as “Qingyuan Kaiwu”)Announced the completion of a Pre-A+ financing round worth tens of millions of yuan in recent days. This round of financing was led byBeijing Pharmaceutical and Health Industry Investment FundLead investment. The funds raised will be used for new product R&D, market promotion, and the construction of production bases, providing strong support for Qingyuan Kaiwu to achieve its domestication and internationalization strategies.

Qingyuan Kaiwu Corporate Environment

Qingyuan Kaiwu was founded in 2021, focusing on the upstream sector of the life sciences and biopharmaceutical industries. It specializes in high-end instrumentation and its industrial applications, leveraging three proprietary core technologies: “precision liquid handling,” “accurate acoustic wave technology,” and “high-precision detection.” By adopting a “flexible, modular” approach, the company constructs laboratory automation systems that provide highly customized, automated, and intelligent solutions for biological sample pre-processing, serving the life sciences services, biopharmaceutical R&D, clinical diagnostics, and synthetic biology sectors.

Since its establishment, Qingyuan Kaiwu has been honored with qualifications such as “National High-Tech Enterprise,” “Beijing Specialized, Refined, Differential, and Innovative SME,” “Beijing Innovative SME,” and “Zhongguancun High-Tech Enterprise,” and has received capital support from investors including Shuimu Ventures, Changfa Development, and Yuanhui Chuangyi.

Wang Dong, founder of Qingyuan Kaiwu, graduated from the Department of Precision Instruments at Tsinghua University. He served as the Head of Instrument R&D at CapitalBio Corporation, a leading domestic genetic testing company, for 15 years. During his tenure, he established two research institutes, focusing on gene diagnosis, cell detection, laboratory automation, intelligent diagnostics, and microfluidics technology. Wang has been honored with numerous titles, including Beijing Capital Science and Technology Innovation Leading Talent, Mao Yisheng Beijing Youth Science and Technology Award, Beijing Young Engineer Model, Zhongguancun High-End Leading Talent, Beijing Science and Technology Star, and Beijing Outstanding Youth. He has led the development of over 90 products; obtained 12 NMPA certificates, 12 CE certificates, one WEEE certificate, and one RoHS certificate; filed more than 120 patent applications; spearheaded the formulation of four national standards; and undertaken more than 10 scientific research projects.

All members of the company’s R&D team come from leading enterprises in the biopharmaceutical sector. With over a decade of deep engagement in the market for life science instruments and equipment—particularly in nucleic acid, protein, and cell detection—they possess profound insights into the needs of the life science and biopharmaceutical industries.

Founder Wang Dong Attended the “Liang·Jianyan – The 7th In Vitro Diagnostics Young Entrepreneurs Forum” Hosted by CAIVD

Qingyuan Kaiwu Wins “Most Investment-Worthy Award”

Driven by substantial demand in the domestic market, Qingyuan Kaiwu has comprehensively deployed its product lines for pre-sequencing sample preparation, pre-mass spectrometry sample preparation, and specialized tools for synthetic biology, establishing differentiated technological barriers for each segment. The company has filed over 50 applications for independent intellectual property rights and independently developed more than 10 products.

Its core “Ultra-Micro Liquid Precision Control Life Science Tool Platform” features China’s exclusive proprietary technologies for precise droplet generation and pipetting, enabling liquid handling across a broad volume range (from milliliters to nanoliters). This life science platform supports full-line multi-omics applications and provides solutions for certain drug development and synthetic biology production scenarios.

Qingyuan Kaiwu’s “Ultra-Micro Liquid Precision Control Life Science Tool Platform” Ranked on the 2024 VBEF Healthcare Industry Innovation List

And with “EoSonics^®FRAG Series Focused Ultrasound Disruptor + EoSBot^®The “NGS-APW” automated pre-sequencing workflow, built on the Seq24 Fully Automated NGS Library Preparation System, enables an integrated “library preparation and construction in one” sample pre-processing model.

It is reported that Qingyuan Kaiwu’s sequencing library preparation workstation and ultrasonic fragmentation workstation have achieved mass production and entered the market, with successful signings of distributors in China’s medical and disease control sectors. Notably, in April, the TGuide LP12 Biomolecule Purification System, jointly developed by Tiangen Biotech and Qingyuan Kaiwu, was officially launched. Meanwhile, the company’s high-throughput tools designed for drug screening and production are scheduled to be released successively.

For this round of financing,Wang Dong, Chairman of Beijing Qingyuan Kaiwu“The financing round has introduced the Beijing Pharmaceutical and Health Fund. With the impetus of this round, Qingyuan Kaiwu aims to accelerate the translation of its innovative products. Staying true to its original mission of ‘addressing major typical needs and developing innovative, practical products,’ Qingyuan Kaiwu is committed to refining products that reach world-leading standards, making it a reality for intelligent manufacturing and innovation from China to serve the world.”

Beijing Pharmaceutical and Health Industry Investment FundQingyuan Kaiwu leverages automation based on ultra-micro liquid precise manipulation as its core technology to develop automated life science tool platforms and consumables for customers, including high-throughput library preparation systems for pre-sequencing sample processing, ultrasonic fragmenters, plasmid extraction systems, ultrasonic pipetting systems, and nucleic acid mass spectrometry spotting systems. These innovations are poised to address the highly customized, integrated, automated, multi-omics, and intelligent needs that remain unmet in China’s life sciences, biopharmaceutical, and clinical diagnostics markets, thereby achieving domestic autonomy and controllability over laboratory automation equipment. Adhering to the principle of patient capital, the Beijing Medical and Health Fund accompanies enterprises and scientists in their long-term endeavors, facilitating the timely market launch of enterprise products and their expansion into the global market.

Beijing Pharmaceutical and Health Industry Investment Fund (Limited Partnership) is a government-guided investment fund established by Beijing Municipality in late 2023, focusing on key sectors such as innovative drugs and innovative medical devices, as well as emerging fields including cell and gene therapy and digital health.